Form 4: OptimizeRx CEO William Febbo Reports Stock Transactions
SEC Form 4 Filing
OptimizeRx CEO William Febbo reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On April 18, 2024, William Febbo, CEO of OptimizeRx Corp, reported transactions involving common stock and restricted stock units.
- 28,895 restricted stock units vested and converted into common stock.
- 782 shares were withheld by the issuer to satisfy tax obligations at a price of $9.35 per share.
- Following these transactions, Febbo directly owns 581,253 shares of OptimizeRx Corp.
- The reporting person's prior holdings were previously inadvertently overstated by four shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings.
Key Dates
| Date | Description |
|---|---|
| 04/18/2023 | Reporting Person was granted 86,685 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 04/18/2024 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 06/12/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.